Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Sees Significant Increase in Short Interest

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 19,200 shares, an increase of 26.3% from the September 30th total of 15,200 shares. Based on an average daily trading volume, of 2,530,000 shares, the short-interest ratio is currently 0.0 days.

Quoin Pharmaceuticals Trading Up 7.6 %

Shares of Quoin Pharmaceuticals stock traded up $0.06 during trading hours on Monday, reaching $0.87. The stock had a trading volume of 664,722 shares, compared to its average volume of 995,833. The firm has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.65. The firm has a market capitalization of $3.46 million, a price-to-earnings ratio of -0.12 and a beta of 1.95. Quoin Pharmaceuticals has a 1 year low of $0.48 and a 1 year high of $6.18.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.36. During the same quarter in the prior year, the company earned ($2.13) EPS. Sell-side analysts forecast that Quoin Pharmaceuticals will post -2.02 EPS for the current year.

Institutional Investors Weigh In On Quoin Pharmaceuticals

An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 30,749 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.77% of Quoin Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 8.63% of the stock is currently owned by institutional investors and hedge funds.

About Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.